Ultragenyx Pharmaceutical Inc. is the subject of a securities class action lawsuit stemming from alleged failures to disclose material information regarding unsuccessful Phase 3 clinical trials for setrusumab (UX143), an investigational treatment for osteogenesis imperfecta. The company's December 26, 2025 announcement regarding the trial failure triggered a significant market reaction, with shares declining 42% from $34.19 to $19.72 per share.
Investors who sustained losses exceeding $100,000 during the relevant trading period must submit lead plaintiff applications by April 6, 2026, to participate in the litigation. Lead plaintiff designation is a procedural requirement in securities class actions, with selected plaintiffs representing the broader investor group throughout the legal process.
The case centers on the disclosure practices of the biopharmaceutical company and whether shareholders received timely notice of clinical trial developments prior to the public announcement. Ultragenyx focuses on rare and ultra-rare genetic diseases, with setrusumab representing a key asset in its development pipeline for treating osteogenesis imperfecta, a genetic disorder characterized by brittle bones.